Effects of doxorubicin and apigenin on chronic myeloid leukemia cells (K562) in vitro : anti-proliferative and apoptosis induction assessments
In this study, we aimed to investigate the effect of the co-treatment with apigenin and doxorubicin (DOX) on K562 cells. Our results show that apigenin (0, 40, 60, 80 ,100 µM) and DOX (0-10 µM) as single therapy, could decrease K562 cell viability (after 24 h of treatment) in a dose-dependent manner. Additionally, the co-treatment with apigenin (60, 80 µM) and 10 µM of DOX led to a greater reduction in cell growth (CI: 0.92 and 0.97) after 24 h of treatment compared to the single DOX treatment (p < 0.05). Consequently, apigenin and DOX, either as single or as co-treatment (24 h of treatment), were indicated to induce apoptosis in K562 cells through morphological studies, RT-qPCR, and western-blot analysis. Eventually, the expressions of Caspase 3, 6, 7, and 9 genes in the single treatment with DOX had higher alteration compared to the co-treatment with DOX and apigenin (p < 0.05).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Natural product research - 37(2023), 19 vom: 01. Okt., Seite 3335-3343 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Noorian, Maryam [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Apigenin |
|---|
| Anmerkungen: |
Date Revised 08.09.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1080/14786419.2022.2069765 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340317485 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340317485 | ||
| 003 | DE-627 | ||
| 005 | 20231226004857.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14786419.2022.2069765 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1134.xml |
| 035 | |a (DE-627)NLM340317485 | ||
| 035 | |a (NLM)35503006 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Noorian, Maryam |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of doxorubicin and apigenin on chronic myeloid leukemia cells (K562) in vitro |b anti-proliferative and apoptosis induction assessments |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a In this study, we aimed to investigate the effect of the co-treatment with apigenin and doxorubicin (DOX) on K562 cells. Our results show that apigenin (0, 40, 60, 80 ,100 µM) and DOX (0-10 µM) as single therapy, could decrease K562 cell viability (after 24 h of treatment) in a dose-dependent manner. Additionally, the co-treatment with apigenin (60, 80 µM) and 10 µM of DOX led to a greater reduction in cell growth (CI: 0.92 and 0.97) after 24 h of treatment compared to the single DOX treatment (p < 0.05). Consequently, apigenin and DOX, either as single or as co-treatment (24 h of treatment), were indicated to induce apoptosis in K562 cells through morphological studies, RT-qPCR, and western-blot analysis. Eventually, the expressions of Caspase 3, 6, 7, and 9 genes in the single treatment with DOX had higher alteration compared to the co-treatment with DOX and apigenin (p < 0.05) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chronic myeloid leukemia | |
| 650 | 4 | |a P53 | |
| 650 | 4 | |a apigenin | |
| 650 | 4 | |a apoptosis | |
| 650 | 4 | |a doxorubicin | |
| 700 | 1 | |a Chamani, Elham |e verfasserin |4 aut | |
| 700 | 1 | |a Salmani, Fatemeh |e verfasserin |4 aut | |
| 700 | 1 | |a Rezaei, Zohreh |e verfasserin |4 aut | |
| 700 | 1 | |a Khorsandi, Khatereh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Natural product research |d 2003 |g 37(2023), 19 vom: 01. Okt., Seite 3335-3343 |w (DE-627)NLM124466303 |x 1478-6427 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2023 |g number:19 |g day:01 |g month:10 |g pages:3335-3343 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14786419.2022.2069765 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2023 |e 19 |b 01 |c 10 |h 3335-3343 | ||